Year: 2025

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

Staff September 16, 2025

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Staff September 16, 2025

Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3...

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Staff September 16, 2025

Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3...

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

Staff September 16, 2025

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

Staff September 16, 2025

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

Staff September 16, 2025

FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

Staff September 16, 2025

FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Staff September 16, 2025

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a...

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Staff September 16, 2025

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a...

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Staff September 16, 2025

Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo...

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Staff September 16, 2025

Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo...

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Staff September 16, 2025

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing...

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Staff September 16, 2025

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing...

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Staff September 16, 2025

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of...

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Staff September 16, 2025

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of...

Year: 2025

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge

The Naderi Center Announces the Rise of “Facial Harmony” as 2025’s Leading Trend in Aesthetic Surgery and Dermatology

Sannabis S.A.S., a Colombia Licensed Cannabis Operator, Addresses U.S. Marijuana Rescheduling and Potential Implications for International Medical Cannabis Travel and Trade

You may have missed